Here it is todays blockbuster. HYALF, great finanicals last week. A fully reporting company. A cancer treatment just got worldwide approval. News just out and volume is building right now. This is a money maker. I am waiting to fill right now.
BIG DOG
Monday May 4, 11:11 am Eastern Time
Company Press Release
SOURCE: Hyal Pharmaceutical Corporation
Solarase(TM) Approved in Germany, Sweden, France and Italy
MISSISSAUGA, Ont., May 4 /CNW-PRN/ - Hyal Pharmaceutical Corporation (NASDAQ/NNM: HYALF - news; TSE: HPC - news) announced today that its lead product Solarase has received regulatory approval for marketing in Germany, Sweden, Italy and France, in addition to the previously announced approval for the United Kingdom. Solarase has been shown to be an effective topical therapy for actinic keratosis or sunspots, the forerunner of one of the most common forms of skin cancer - squamous cell carcinoma.
Actinic Keratosis is a sun exposure related precancerous skin condition affecting one in six adults worldwide. The current market for various treatments for this condition in the U.S.A. alone is approximately US$240 million per annum.
''This important milestone further validates Hyal's HIT(TM) technology and adds value to Solarase for potential partners,'' said Dr. Zenas B. Noon, Jr., Hyal's President and CEO. ''We also expect to file a submission to the FDA in the third quarter of this year seeking marketing approval for the USA. Hyal is currently seeking marketing approval for Solarase in Canada, Australia and New Zealand.''
Solarase utilizes Hyal's proprietary HIT technology. Compared to other Actinic Keratosis treatments, Solarase is non-invasive, non-scarring and is extremely well tolerated by patients. Hyal received a patent from the United States Patent Office in January 1997 protecting Solarase.
Hyal Pharmaceutical Corporation is a drug delivery company engaged in research and development and is seeking worldwide commercialization of pharmaceutical formulations utilizing its proprietary Hyaluronan Induced Targeting (HIT)(TM) Technology and Hyaluronan Improved Liposome Technology (HILT)(TM).
This news release may contain forward-looking statements relating to the future performance of Hyal. Forward-looking statements, specifically those concerning future performance, are subject to certain risks and uncertainties, and actual results may differ materially. These risks and uncertainties are detailed from time to time in the Company's filings with the appropriate securities commissions.
SOURCE: Hyal Pharmaceutical Corporation
-------------------------------------------------------------------------------- |
